One of the most topical global issues in 2021 was the struggle against COVID-19. The creation of vaccines and the global agitation about them has attracted investors to the biotech sector.

Here is a list of the Top 3 representative companies in this segment. The stock of these three biotech companies demonstrated the most noticeable growth in 2021. One more selection criterion was their average market capitalisation: from $10 to $200 billion.

The list consists of BioNTech, Moderna, and Bio-Techne.

1. BioNTech

The company was founded in Germany in 2008. It specialises in designing and manufacturing active immunotherapy for the individual treatment of cancer and infections.

The company focuses on drugs based on matrix RNA, cell therapy, antibodies, and immunomodulators. BioNTech became known after developing a vaccine to fight the coronavirus in cooperation with Pfizer.

In 2021, BioNTech SE (NASDAQ: BNTX) stock saw a remarkable 196.1% growth.

Since January 2021, the share price of BioNTech SE (NASDAQ: BNTX) has grown 196.1% from $81.52 to $241.4. At the time of preparing this article, the market capitalisation of the company was $59.6 billion.

On 9 August 2021, the shares reached the $447.23 all-time high, surging 15% overnight. On that day, BioNTech reported that, in July 2021, it had supplied over 1 billion doses of the anti covid vaccine together with Pfizer, which was 43% more than in June 2021.

However, at the beginning of November 2021, the Science Council of the BMJ published research, which showed that Ventavia Research Group had made several serious mistakes while conducting clinical trials for the Pfizer-BioNTech vaccin, resulting in false test results. Consequently, on 5 November 2021, BioNTech's shares dropped 21% to $216.64.

Following the publishing of the results of a new study by researchers of the University of Oxford, which suggested that the Omicron variant could hit individuals that are double-vaccinated against Covid, BioNTech shares embarked on a 16% decline that lasted 6 trading sessions.

BioNTech share price chart
Past performance is not a reliable indicator of future results or future performance.

2. Moderna

Moderna, an American biotech company founded in 2010, works on treating immune oncology, and rare, infectious, cardiovascular, and autoimmune diseases. It uses matrix RNA.

At the time of writing this article, the share price of Moderna, Inc. (NASDAQ: MRNA) was $241.44. In 2021, the stock of the biotech company has seen notable growth of 131.1%. The company's market capitalisation has now reached $98.4 billion.

The shares of Moderna, Inc. (NASDAQ: MRNA) grew 131.1% in 2021.

On 16 July 2021, we heard that Moderna stock would be appearing on the S&P 500 list. This news made the company's shares rise 10% to $286.43. The high of 2021 was reached on 9 August, when the shares saw a 17% growth to $484.47.

Moderna's shares surged following the news that the anti-coronavirus drug it had designed was preliminarily registered in Australia, and permission was granted in Switzerland to proceed with vaccinating adolescents aged 12 to 17 years.

However, further to the doubtful efficacy of the existing vaccines against the Omicron variant, Moderna shares plunged into a prolonged slump in December 2021. The shares have been falling for six trading sessions in a row, losing a total of 18%.

Moderna share price chart
Past performance is not a reliable indicator of future results or future performance.

3. Bio-Techne

This American company was founded in 1976 and was initially called R&D Systems. It began operating under its new name – Bio-Techne – in 2014. Bio-Techne designs, produces, and sells reagents, instruments, and equipment for medical research and clinical diagnostics.

The company owns brands such as R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, BiosPacific, Advanced Cell Diagnostics, Exosome Diagnostics, Asuragen, and RNA Medical.

In 2021, Bio-Techne Corporation (NASDAQ: TECH) stock grew 56.8%.

Since January 2021, the shares of Bio-Techne Corporation (NASDAQ: TECH) increased 56.8% from $317.55 to $497.79. At the time of writing this article, the market capitalisation of the company was $19.4 billion.

Bio-Techne highest share price reached in 2021 is $538.88. Growth was fuelled by the creation of a new platform for human stem cell proliferation and storage.

In December 2021, the company announced the purchase of Wilson Wolf – the leader in the development, production, and commercialisation of cell therapy technology.

Moreover, the management of Bio-Techne was reshuffled. Two new appointments were announced on separate dates: a new president of the protein science segment, and a senior vice president of human resources.

This breaking news in December 2021 was the key driver of growth for Bio-Techne stock.

Bio-Techne share price chart
Past performance is not a reliable indicator of future results or future performance.

The biotech sector is not only attractive for its vaccine industry

The Top 3 biotech companies the stock of which grew most in 2021 are BioNTech, Moderna, and Bio-Techne.

The list demonstrates that the strongest momentum this year was gained by the companies working on anti-coronavirus vaccines.

Nevertheless, Bio-Techne on the list proves that investor interest in biotechnology is not only owing to biotech companies' response to the pandemic. The biotech sector is becoming as attractive for investments as IT is. The growing adoption of biotechnology in clinical research is accelerating the expansion of the sector, making it more and more promising.

This material and the information contained therein are for informational purposes only and should in no way be construed as providing investment advice for the purposes of the Investment Companies Act 87 (I) 2017 of the Republic of Cyprus, or any other form of personal advice or recommendation relating to certain types of transactions in certain types of financial instruments.

Material is prepared by

Server is the guru of searching for market insights. Since 2019 he writes about everything that might be useful to the investor, focusing on the stock market and its assets.